4 Results for "

AR-NTD

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "AR-NTD" in MCE Product Catalog:

Cat. No.: HY-109070
CAS No.: 1203490-23-6
Purity:  99.78%
Synonyms: EPI-002
Target:  

Androgen Receptor

Research Areas:  

Cancer

Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC50 of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC) .
loading...
    loading...
Cat. No.: HY-149433
CAS No.: 3042820-12-9
Purity:  99.93%
Research Areas:  

Cancer

BWA-522 is an orally active PROTAC degrader targeting full-length androgen receptor (AR-FL) and androgen receptor splice variant 7 (AR-V7). BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor, suppresses AR downstream signaling proteins and induces cancer cells apoptosis. BWA-522 inhibits tumor growth in LNCaP xenograft mouse model. BWA-522 can be used for the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-149434
CAS No.: 3032601-92-3
Research Areas:  

Cancer

PROTAC AR-NTD antagonist 1 (compound 18) is a small molecule protein-targeting chimera (PROTACs) targeting the Androgen Receptor AR-V7. PROTAC AR-NTD antagonist 1 antagonizes the N-terminal domain of AR (AR-NTD), degrades AR-V7 protein, and induces apoptosis in prostate cancer (PC) cells. The efficiencies of PROTAC AR-NTD antagonist 1 in degrading AR-V7 in VCaP cells were 62.2% (1 μM) and 71.1% (5 μM), respectively .
loading...
    loading...
Cat. No.: HY-109070R
CAS No.: 1203490-23-6
Synonyms: EPI-002 (StandARd)
Research Areas:  

Cancer

Ralaniten (Standard) is the analytical standard of Ralaniten (HY-109070). This product is intended for research and analytical applications. Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC50 of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC) .
loading...
    loading...